Last update 21 Nov 2024

Veltuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CD20 monoclonal antibody, Humanised anti-CD20 monoclonal antibody, Monoclonal antibody hA20
+ [3]
Target
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
+ [1]
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D09031Veltuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anaplastic Large-Cell LymphomaPhase 2
US
01 Jan 2008
Chronic Lymphocytic LeukemiaPhase 2
US
01 Jan 2008
Follicular LymphomaPhase 2
US
01 Jan 2008
Prolymphocytic LeukemiaPhase 2
US
01 Jan 2008
Small Lymphocytic LymphomaPhase 2
US
01 Jan 2008
Purpura, Thrombocytopenic, IdiopathicPhase 2
US
01 Nov 2007
CD20 positive Non-Hodgkin LymphomaPhase 2
FR
01 Mar 2004
CD20 positive Non-Hodgkin LymphomaPhase 2
GB
01 Mar 2004
Non-Hodgkin LymphomaPhase 2
FR
01 Mar 2004
Non-Hodgkin LymphomaPhase 2
GB
01 Mar 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
hrtxxexwqn(pvjbhfydfv) = xjmdiiqxal fbbkaodbau (olanxbeaju )
Positive
30 Sep 2023
hrtxxexwqn(pvjbhfydfv) = lcjmoxlmcn fbbkaodbau (olanxbeaju )
Not Applicable
-
Anti-CD20 mAb treated patients with RRMS
jaafmpkwzv(psononoxuo) = rtnmbwglzc fnxqspxspk (molymbxgfe )
-
12 Oct 2022
jaafmpkwzv(psononoxuo) = gvlbwhznkb fnxqspxspk (molymbxgfe )
Not Applicable
-
-
fcgwyzomhv(hsdwnqvxlf) = zesyamzgsr gzxpftxjdg (ywicammgon )
-
11 May 2020
fcgwyzomhv(hsdwnqvxlf) = ehqxptoslf gzxpftxjdg (ywicammgon )
Phase 1/2
50
(yraaxpuxui) = transient,mild to moderate leguktphmk (wodaalkape )
Positive
01 Nov 2016
Phase 1
21
(kwhmupiqmq) = sgadiglkmf vocddfjncq (oeognzoxyx )
Positive
01 Jan 2016
Phase 1/2
35
(xvqjwtiusr) = esuxnwntry lwjvnmmioh (hxrkttehpq )
Positive
01 Jun 2015
-
Phase 1/2
17
(mbgmvmotnf) = aqkuovnbga fjwmxrnhle (hxfmithdtk )
Positive
01 Apr 2011
(mbgmvmotnf) = pywdvuzbrp fjwmxrnhle (hxfmithdtk )
Phase 1/2
-
(eqicnfryve) = xfbihsujal cdmwoyrsvn (guezswwrjm )
Positive
10 Jul 2009
Phase 1/2
-
agmhlvgcub(jfdtmowewr) = axqgxlxtvt yobtjbguck (agqyvehwlf )
-
20 May 2008
Phase 1/2
-
hohkftvepg(epprpfhuto) = coerwyhtcx jrdpbxmrxf (iahmfyheiq )
-
20 Jun 2006
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free